Is Exagen Inc (XGN) overvalued? · rev $55.6M
Exagen Inc (XGN) is a diagnostics & research company listed on US.
This page asks whether Exagen Inc (XGN) looks expensive on cached numbers — not a short thesis.
Latest reported XGN revenue for 2024-12-31 was $55.6M. Net income was -$15.1M. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. XGN currently screens at market cap $154.1M.
XGN currently screens at market cap $154.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next XGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the XGN stock page for the full model, not this heading.
Not investment advice.